John M. Rothman

Corporate Officer/Principal presso TYME TECHNOLOGIES, INC.

75 anni

Health Technology

Consumer Services

Profilo

John M.
Rothman is currently the Executive Vice President-Product Development at Tyme Technologies, Inc. He previously worked as the EVP-Clinical & Scientific Operations at Advaxis, Inc. from 2011 to 2013.
He also worked as the Chief Scientific Officer at Race Oncology Ltd.
Dr. Rothman earned a doctorate degree from Tulane University School of Medicine.

Posizioni attive di John M. Rothman

Società	Posizione	Inizio
TYME TECHNOLOGIES, INC.	Corporate Officer/Principal	19/08/2020

Tutte le posizioni attive di John M. Rothman

Precedenti posizioni note di John M. Rothman

Società	Posizione	Fine
RACE ONCOLOGY LIMITED	Chief Tech/Sci/R&D Officer	01/10/2019
AYALA PHARMACEUTICALS, INC.	Chief Operating Officer	09/12/2011

Vedi nel dettaglio l'esperienza di John M. Rothman

Formazione di John M. Rothman

Tulane University School of Medicine

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di John M. Rothman

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
RACE ONCOLOGY LIMITED	Health Technology

Aziende private	2
Tyme Technologies, Inc. Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.	Health Technology
Advaxis, Inc. Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.	Health Technology

Aziende private